cdc7 in 1

Cdc7-IN-1 is a highly selective and ATP competitive inhibitor of Cdc7 kinase (IC50: 0.6 nM at 1 mM ATP). It potently inhibits Cdc7 activity in cancer cells and effectively induces cell death.

Cdc7-IN-15 (Example 108) 是 cdc7激酶抑制剂，具有用于癌症研究的潜力。

Cdc7-IN-17 是CDC7的有效抑制剂，IC50值小于10 μM，可用于癌症研究。

Cdc7-IN-12 (compound 1) 是 CDC7的有效抑制剂(IC50为 <1 nM)，在癌症研究中具有潜力。Cdc7-IN-12 在人结肠癌细胞COLO205 中表现出抗增殖活性，IC50为 100-1000 nM。

Cdc7-IN-19 (compound 1-1) 是一种有效的CDC7抑制剂，对 Cdc7/DBF4 酶的IC50为 1.49 nM。

Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].

Cdc7-IN-14 (compound 82) is a highly potent inhibitor of CDC7, demonstrating an IC50 value of less than 1 nM. This compound, Cdc7-IN-14, exhibits promising potential for cancer research [1].

(S)-Cdc7-IN-18, a potent CDC7 inhibitor, effectively impedes the overactivation of MCM2, a crucial tumor cell marker, induced by huCdc7 overexpression. Consequently, it inhibits the aberrant proliferation of tumor cells. This compound, exhibits promise for cancer disease research [1].

Cdc7-IN-18 (compound 1-2) is a highly effective inhibitor of the CDC7 enzyme. It has an IC 50 value of 1.29 nM for the Cdc7/DBF4 enzyme. In addition, this compound exhibits strong antiproliferative activities, with an IC 50 value of 53.62 nM in COLO205 cells [1].

Cdc7-IN-10 是一种 Cdc7 的高效抑制剂 (IC50≤1 nM)，能够用于增殖性疾病的研究。

Cdc7-IN-11 是一种 Cdc7 的高效抑制剂 (IC50≤1 nM)，能够用于增殖性疾病的研究。

LY3143921 ((S)-Example 2) 具有广泛的体外抗癌活性，是口服有效的CDC7激酶抑制剂。

Cdc7-IN-9 是可以用于癌症研究的，Cdc7的有效抑制剂。

Cdc7-IN-8, a potent inhibitor, targets Cdc7, a serine/threonine kinase responsible for activating MCM promotion through phosphorylation of the microchromosome maintenance protein (MCM protein). MCM protein, an essential component of DNA replication initiation, plays a crucial role. Cdc7-IN-8 holds promise in cancer disease research (WO2021032170A1, compound 1-1/1-2) [1].

LY3143921 ((S)-Example 2) hydrate 是一种具有口服活性的 CDC7激酶抑制剂。LY3143921 hydrate 表现出广泛的体外抗癌活性。